Plasmin-Alpha-2-Antiplasmin (PAP) Complex
Plasmin-Alpha-2-Antiplasmin complex (PAP) is an index of recent fibrinolytic activity.
Alpha-2-antiplasmin (a-2-antiplasmin) is a single chain 70 kD plasmin inhibitor which rapidly reacts with plasmin to form the inactive Plasmin-Alpha-2-Antiplasmin complex (PAP). Synthesized by the liver, α2-antiplasmin circulates in plasma at a concentration of approximately 1 µM (70 µg/mL), with 20% being cross-linked when blood clots. The formation of the PAP complex is a two step process. First, the lysine binding sites of plasmin and the carboxylterminal region of α2-antiplasmin form a reversible complex. In the second step, cleavage of the peptide bond of the inhibitor forms the irreversible complex. α2-antiplasmin is consumed during thrombolytic therapy. Increased PAP complex formation is accompanied by increased fibrin formation and an increased reactive plasminemia. Accordingly, a correlation between the level of fibrin split products and the level of PAP complexes exists.
TECHNOZYM® PAP Complex ELISA Kit
For the determination of the concentration of Plasmin-α2-Antiplasmin complexes in plasma. The Plasmin-α2-Antiplasmin Complex ELISA Kit is based on a monoclonal capture antibody which is directed against the neoantigenic site on the complex, an epitope only expressed in the complexes themselves. Therefore, this antibody is specific for complexes only and does not recognize free α2-antiplasmin or plasminogen. Detection of bound complexes is performed with a second monoclonal peroxidase-labeled antibody recognizing a different epitope on the complex.